top of page

Metabolic Biomarkers of Clinical Outcomes in SMI

Workstream 3

The investigation of metabolic biomarkers in psychiatric disorders is at an early stage, with evidence suggesting that metabolic problems are both causes and consequences of severe mental illness [25]. More work is needed to identify robust metabolic biomarkers across the mood-psychosis spectrum of SMI and to identify the mechanisms by which these biomarkers impact on clinical outcomes. Additionally, the control of metabolism is highly circadian (with, for example, strong pulses of lipolysis overnight) and there is considerable interest in ‘chronometabolic’ interventions for obesity and type 2 diabetes (such as time restricted eating). We will therefore also study sleep/circadian rhythms at high resolution to assess how circadian disruption influences observed associations between metabolism and SMI outcomes.

Workstream three will deliver new insights into mechanisms linking metabolic markers, sleep/circadian rhythms and clinical outcomes in young adults with SMI. The innovative ‘deep-phenotyping’ approach outlined above will act as a prototype for future up- scaled UK-wide data collection platforms designed to assess metabolic and circadian parameters and clinical outcomes in SMI, for example, within future prospective studies and clinical trials.

Power in Numbers







Team Members 

Olivia Walker

Editor in Chief

Dan Mitchell

Assistant Manager

Noah Patterson

Programming Editor

Tess Anderson

Art Director

bottom of page